
Mikael S. Lindström

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7730916/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways. Cell Death and Differentiation, 2022, 29, 972-982.	11.2	47
2	Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward. Cancers, 2022, 14, 2126.	3.7	31
3	SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma. Oncogene, 2021, 40, 5066-5080.	5.9	12
4	The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Science Advances, 2021, 7, .	10.3	25
5	The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. Cell Death and Differentiation, 2020, 27, 773-789.	11.2	35
6	Identification of functionally distinct and interacting cancer cell subpopulations from glioblastoma with intratumoral genetic heterogeneity. Neuro-Oncology Advances, 2020, 2, vdaa061.	0.7	7
7	Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. Cancer Research, 2020, 80, 1538-1550.	0.9	19
8	Expanding the scope of candidate prognostic marker IGFBP2 in glioblastoma. Bioscience Reports, 2019, 39, .	2.4	8
9	Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis. Oncogene, 2018, 37, 2351-2366.	5.9	181
10	DNA damage-induced dynamic changes in abundance and cytosol-nuclear translocation of proteins involved in translational processes, metabolism, and autophagy. Cell Cycle, 2018, 17, 2146-2163.	2.6	9
11	Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype. Cancer Research, 2018, 78, 5901-5916.	0.9	12
12	Human cytomegalovirus and Herpes Simplex type I virus can engage RNA polymerase I for transcription of immediate early genes. Oncotarget, 2017, 8, 96536-96552.	1.8	6
13	Role of ribosomal protein mutations in tumor development (Review). International Journal of Oncology, 2016, 48, 1313-1324.	3.3	150
14	NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape. Scientific Reports, 2015, 5, 16495.	3.3	40
15	Disruption of the 5S RNP–Mdm2 interaction significantly improves the erythroid defect in a mouse model for Diamond-Blackfan anemia. Leukemia, 2015, 29, 2221-2229.	7.2	35
16	Abstract 2082: Control and function of the PROX1 transcription factor in malignant glioma. , 2015, , .		0
17	Loss of Nucleolar Histone Chaperone NPM1 Triggers Rearrangement of Heterochromatin and Synergizes with a Deficiency in DNA Methyltransferase DNMT3A to Drive Ribosomal DNA Transcription. Journal of Biological Chemistry, 2014, 289, 34601-34619.	3.4	51
18	mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels. Cancer Biology and Therapy, 2014, 15, 1499-1514.	3.4	27

Mikael S. Lindström

#	Article	IF	CITATIONS
19	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in <i>p53</i> . Genes and Development, 2014, 28, 58-70.	5.9	156
20	The Nucleolus as a Stress Response Organelle. , 2013, , 251-273.		8
21	PDGF and PDGF receptors in glioma. Upsala Journal of Medical Sciences, 2012, 117, 99-112.	0.9	142
22	Transcription factor PROX1: its role in development and cancer. Cancer and Metastasis Reviews, 2012, 31, 793-805.	5.9	118
23	Elucidation of Motifs in Ribosomal Protein S9 That Mediate Its Nucleolar Localization and Binding to NPM1/Nucleophosmin. PLoS ONE, 2012, 7, e52476.	2.5	20
24	p53 -Dependent and -Independent Nucleolar Stress Responses. Cells, 2012, 1, 774-798.	4.1	85
25	Uncoupling of the ERα regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines. Biochemical and Biophysical Research Communications, 2011, 405, 581-587.	2.1	8
26	Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. Journal of Oncology, 2011, 2011, 1-11.	1.3	27
27	Brain Abnormalities and Glioma-Like Lesions in Mice Overexpressing the Long Isoform of PDGF-A in Astrocytic Cells. PLoS ONE, 2011, 6, e18303.	2.5	21
28	PROX1 is a predictor of survival for gliomas WHO grade II. British Journal of Cancer, 2011, 104, 1747-1754.	6.4	36
29	NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling. Biochemistry Research International, 2011, 2011, 1-16.	3.3	250
30	Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic Gliomas. Journal of Neuropathology and Experimental Neurology, 2010, 69, 129-138.	1.7	47
31	Silencing of Ribosomal Protein S9 Elicits a Multitude of Cellular Responses Inhibiting the Growth of Cancer Cells Subsequent to p53 Activation. PLoS ONE, 2010, 5, e9578.	2.5	71
32	An ARF-Independent c-MYC-Activated Tumor Suppression Pathway Mediated by Ribosomal Protein-Mdm2 Interaction. Cancer Cell, 2010, 18, 231-243.	16.8	185
33	Emerging functions of ribosomal proteins in gene-specific transcription and translation. Biochemical and Biophysical Research Communications, 2009, 379, 167-170.	2.1	152
34	Ribosomal Protein S9 Is a Novel B23/NPM-binding Protein Required for Normal Cell Proliferation. Journal of Biological Chemistry, 2008, 283, 15568-15576.	3.4	107
35	Putting a Finger on Growth Surveillance: Insight into MDM2 Zinc Finger-Ribosomal Protein Interactions. Cell Cycle, 2007, 6, 434-437.	2.6	60
36	Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation. Molecular and Cellular Biology, 2007, 27, 1056-1068.	2.3	131

Mikael S. Lindström

#	Article	IF	CITATIONS
37	Targeted Inactivation of Mdm2 RING Finger E3 Ubiquitin Ligase Activity in the Mouse Reveals Mechanistic Insights into p53 Regulation. Cancer Cell, 2007, 12, 355-366.	16.8	228
38	B23 and ARF: Friends or Foes?. Cell Biochemistry and Biophysics, 2006, 46, 79-90.	1.8	44
39	p16lNK4aand laminin-5γ2 chain expression during the progression of cervical neoplasia. Acta Oncológica, 2006, 45, 676-684.	1.8	3
40	Essential Role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability. Journal of Biological Chemistry, 2006, 281, 18463-18472.	3.4	58
41	p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Modern Pathology, 2005, 18, 629-637.	5.5	41
42	Predictive Significance of the Alterations of p16INK4A, p14ARF, p53, and Proliferating Cell Nuclear Antigen Expression in the Progression of Cervical Cancer. Clinical Cancer Research, 2004, 10, 2407-2414.	7.0	96
43	Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. Oncogene, 2003, 22, 4993-5005.	5.9	78
44	A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Letters, 2002, 180, 211-221.	7.2	15
45	Role of genetic and epigenetic changes in Burkitt lymphoma. Seminars in Cancer Biology, 2002, 12, 381-387.	9.6	98
46	Inactivation of Myc-induced p53-dependent apoptosis in human tumors. Apoptosis: an International Journal on Programmed Cell Death, 2001, 6, 133-137.	4.9	27
47	p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene, 2001, 20, 2171-2177.	5.9	88
48	MdmX Binding to ARF Affects Mdm2 Protein Stability and p53 Transactivation. Journal of Biological Chemistry, 2001, 276, 25336-25341.	3.4	54
49	Immunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus. Experimental Cell Research, 2000, 256, 400-410.	2.6	79